Healthcare provider profile · identity verified

Alexander Schneider, DO

Family Practice · NILES, MI · NPI 1609303098

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	194	69
Gabapentin	Gabapentin	173	41
Levothyroxine Sodium	Levothyroxine Sodium	141	43
Lisinopril	Lisinopril	139	48
Amlodipine Besylate	Amlodipine Besylate	121	41
Pantoprazole Sodium	Pantoprazole Sodium	96	30
Hydrochlorothiazide	Hydrochlorothiazide	94	31
Metformin Hcl	Metformin Hcl	93	33
Rosuvastatin Calcium	Rosuvastatin Calcium	90	24
Metformin Hcl Er	Metformin Hcl	84	19
Omeprazole	Omeprazole	76	24
Albuterol Sulfate Hfa	Albuterol Sulfate	73	28
Ozempic	Semaglutide	73	13
Trazodone Hcl	Trazodone Hcl	71	24
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	69	suppressed
Metoprolol Succinate	Metoprolol Succinate	67	21
Montelukast Sodium	Montelukast Sodium	64	16
Duloxetine Hcl	Duloxetine Hcl	59	22
Sertraline Hcl	Sertraline Hcl	58	16
Furosemide	Furosemide	56	23
Buspirone Hcl	Buspirone Hcl	54	17
Losartan Potassium	Losartan Potassium	53	19
Valsartan	Valsartan	52	22
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	49	17
Meloxicam	Meloxicam	46	17
Tamsulosin Hcl	Tamsulosin Hcl	46	16
Clopidogrel	Clopidogrel Bisulfate	45	16
Simvastatin	Simvastatin	45	15
Ventolin Hfa	Albuterol Sulfate	45	23
Ibuprofen	Ibuprofen	43	11
Metoprolol Tartrate	Metoprolol Tartrate	41	17
Mounjaro	Tirzepatide	41	suppressed
Eliquis	Apixaban	39	suppressed
Prednisone	Prednisone	38	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	34	14
Famotidine	Famotidine	32	13
Fluticasone Propionate	Fluticasone Propionate	32	11
Jardiance	Empagliflozin	32	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	suppressed
Atenolol	Atenolol	31	12
Baclofen	Baclofen	31	suppressed
Diclofenac Sodium	Diclofenac Sodium	31	suppressed
Trulicity	Dulaglutide	30	suppressed
Alendronate Sodium	Alendronate Sodium	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	suppressed
Alprazolam	Alprazolam	26	suppressed
Tramadol Hcl	Tramadol Hcl	26	suppressed
Spironolactone	Spironolactone	25	suppressed
Ondansetron Odt	Ondansetron	24	11
Carvedilol	Carvedilol	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	23	19
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	23	suppressed
Cephalexin	Cephalexin	21	18
Dicyclomine Hcl	Dicyclomine Hcl	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	21	11
Potassium Chloride	Potassium Chloride	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Pravastatin Sodium	Pravastatin Sodium	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	13
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	12
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Glipizide	Glipizide	18	suppressed
Allopurinol	Allopurinol	17	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	17	suppressed
Donepezil Hcl	Donepezil Hcl	16	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Spiriva Respimat	Tiotropium Bromide	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	13	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Testosterone Cypionate	Testosterone Cypionate	12	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	11	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	11	suppressed
Ibu	Ibuprofen	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error